2019 - PRESS RELEASES

Written on . Posted in GFB'S Press Releases .

Myonexus Therapeutics recieves orphan drug designation for Myo-102 - Myonexus January 2nd 2019

Myonexus Therapeutics announces accelerated acquisition by Sarepta Therapeutics. - 2019

Clinical Update: Myo-101 For LGMD Type 2E Business update: Myonexus Acquisition - Sarepta - february 27 2019

Distrofia dei cingoli, Sarepta decide di acquisire Myonexus - Osservatorio Malattie Rare - march 12 2019

Distrofia dei cingoli 2E, primi risultati clinici favorevoli per la terapia genica - Osservatorio Malattie Rare OMAR -  April 12 2019

How an Ohio Kids hospital Quitly Became Groung Zero for Gene Therapy - Xconomy  -  april 15  2019

Gene Delivery for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)  by Isolated Limb Infusion - PubMed.gov - July 2019

La terapia genica  SRP-9003 mostra risultati molto incoraggianti a 9 mesi nella distrofia dei cingoli - Sarepta Reports - October 9 2019

Distrofia dei cingoli 2E, nuovi risultati positivi per la terapia genica SRP-9003 - Osservatorio Malattie Rare OMAR - October 22 2019